BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance.

Duarte, Alexandra A; Gogola, Ewa; Sachs, Norman; Barazas, Marco; Annunziato, Stefano; R de Ruiter, Julian; Velds, Arno; Blatter, Sohvi Tuulikki; Houthuijzen, Julia M; van de Ven, Marieke; Clevers, Hans; Borst, Piet; Jonkers, Jos; Rottenberg, Sven (2018). BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance. Nature methods, 15(2), pp. 134-140. Nature Publishing Group 10.1038/nmeth.4535

Text nmeth.4535.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (1MB) | Request a copy

Poly(ADP-ribose) polymerase inhibition (PARPi) is a promising new therapeutic approach for the treatment of cancers that show homologous recombination deficiency (HRD). Despite the success of PARPi in targeting HRD in tumors that lack the tumor suppressor function of BRCA1 or BRCA2, drug resistance poses a major obstacle. We developed three-dimensional cancer organoids derived from genetically engineered mouse models (GEMMs) for BRCA1- and BRCA2-deficient cancers. Unlike conventional cell lines or mammospheres, organoid cultures can be efficiently derived and rapidly expanded in vitro. Orthotopically transplanted organoids give rise to mammary tumors that recapitulate the epithelial morphology and preserve the drug response of the original tumor. Notably, GEMM-tumor-derived organoids can be easily genetically modified, making them a powerful tool for genetic studies of tumor biology and drug resistance.

Interest & Impact

Downloads

0 since deposited on 18 Apr 2018
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item